Get the Stockscreener App
52.40
0.58%
-0.3591
Dianthus Therapeutics Inc stock is traded at $52.40, with a volume of 225.27K.
It is down -0.58% in the last 24 hours and up +23.11% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$52.76
Open:
$52.41
24h Volume:
225.27K
Relative Volume:
0.32
Market Cap:
$2.25B
Revenue:
$4.85M
Net Income/Loss:
$-114.75M
P/E Ratio:
-16.12
EPS:
-3.25
Net Cash Flow:
$-100.36M
1W Performance:
+18.95%
1M Performance:
+23.11%
6M Performance:
+137.36%
1Y Performance:
+135.44%
1-Day Range:
$51.47
$53.79
1-Week Range:
$42.70
$54.00
52-Week Range:
$13.37
$54.00
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
52.44 | 2.26B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | Truist | Buy |
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: Exploring a Potential 23% Upside in the Biotech Sector - DirectorsTalk Interviews
Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last? - Yahoo Finance
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 10.3%What's Next? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 46.6 USD By Investing.com - Investing.com India
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month HighShould You Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 46.6 USD - Investing.com
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Up 47.4% in December - MarketBeat
First Week of March 20th Options Trading For Dianthus Therapeutics (DNTH) - Nasdaq
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.1%Should You Sell? - MarketBeat
Published on: 2026-01-15 20:27:08 - baoquankhu1.vn
Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Is Dianthus Therapeutics Inc. currently under institutional pressureJuly 2025 Setups & Growth Oriented Trading Recommendations - bollywoodhelpline.com
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year HighShould You Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at $45.56 By Investing.com - Investing.com Nigeria
Trading Recap: How Dianthus Therapeutics Inc stock reacts to bond yieldsWeekly Stock Summary & Free Safe Capital Growth Stock Tips - Bộ Nội Vụ
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 12%Here's What Happened - MarketBeat
Breakout Zone: Whats the RSI of Dianthus Therapeutics Inc stock2025 Risk Factors & High Accuracy Swing Trade Signals - baoquankhu1.vn
Dianthus Therapeutics stock hits 52-week high at $45.56 - Investing.com
Fed Watch: How Dianthus Therapeutics Inc stock responds to policy changesJuly 2025 Snapshot & Weekly High Momentum Picks - Bộ Nội Vụ
Assessing Dianthus Therapeutics (DNTH) Valuation As Price To Book Sits Near 3x And Shares Show Mixed Returns - Yahoo Finance
Dianthus Therapeutics (DNTH) Investor Outlook: A Biotechnology Gem with a 66.92% Upside - DirectorsTalk Interviews
Will Dianthus Therapeutics Inc. stock gain from lower inflation2025 Institutional Moves & Low Risk Profit Maximizing Plans - Улправда
Can Dianthus Therapeutics Inc. stock hit record highs againJuly 2025 Sentiment & Risk Managed Investment Entry Signals - Улправда
Why Dianthus Therapeutics Inc. stock could outperform in 2025Portfolio Update Summary & Real-Time Volume Triggers - Улправда
DNTH: Analyst Raises Price Target to $63, Maintains Buy Rating | - GuruFocus
Truist Financial Raises Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $63.00 - MarketBeat
Market Outlook: What technical charts say about Dianthus Therapeutics Inc. stock2025 Analyst Calls & Long-Term Investment Growth Plans - Улправда
Cash per share of Dianthus Therapeutics, Inc. – LS:A3ERZ4 - TradingView — Track All Markets
San Gabriel Valley Tribune - FinancialContent
Laser Focus WorldDianthus Therapeutics, Inc.Common Stock (Nasdaq:DNTH) Stock Quote - FinancialContent
Why Dianthus Therapeutics Inc. (87E) stock fits value portfolios2026 world cup usa national team quarterfinals goalkeepers high defensive line odds analysis breakdown - Улправда
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Dianthus Therapeutics Enters Oversold Territory (DNTH) - Nasdaq
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Biotech targeting severe autoimmune diseases to present at JPM event - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.3% – Here’s Why - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.3%What's Next? - MarketBeat
Dianthus Therapeutics, Inc. $DNTH Stake Lessened by Moody Aldrich Partners LLC - MarketBeat
ETF Watch: Why Dianthus Therapeutics Inc stock could outperform in 2025Market Movement Recap & AI Enhanced Execution Alerts - moha.gov.vn
Dianthus, Nanjing Leads Biolabs initiate Phase 1 trial of LBL-047 - MSN
Leads Biolabs and Dianthus Therapeutics Initiate Phase 1 Trial for LBL-047 (DNTH212), a Bifunctional Fusion Protein Targeting Autoimmune Disorders - Quiver Quantitative
Leads Biolabs And Dianthus Therapeutics Announce Initiation Of Phase 1 Trial Of LBL-047 (Dnth212) In Healthy Volunteers And Patients With Systemic Lupus Erythematosus - TradingView — Track All Markets
New lupus drug test begins, aiming for simple self-injections every month - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) Given “Outperform” Rating at Wedbush - Defense World
Wedbush Reiterates Outperform Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics Earnings Notes - Trefis
How big funds are accumulating Dianthus Therapeutics Inc. (87E) stockPortfolio Return Report & High Conviction Investment Ideas - Улправда
Aug Closing: How big funds are accumulating Dianthus Therapeutics Inc. (87E) stockJuly 2025 Recap & Daily Profit Focused Screening - Улправда
Wall Street Recap: Is Dianthus Therapeutics Inc. stock overvalued by current metricsCPI Data & AI Enhanced Trading Signals - Улправда
First Week of August 2026 Options Trading For Dianthus Therapeutics (DNTH) - Nasdaq
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):